Hexima Ltd (HXL)
20mins delayed
Movement
1 Year Return
Hexima Ltd Chart
| Share price | |
| Last | |
| Change | |
| Volume | |
| Turnover | |
| Market Cap | $19.86 million |
| Today's Movement | |
| Prev. Close | |
| Open | |
| Day Range | - |
| VWAP | |
| Historical Stats | |
| 52w Range | - |
| 4w Avg Volume | |
| 4w Avg Turnover | |
| (delayed) | |
HXL Statistics
15 January
1,764 / 2,260
ASX Size Rank
1yr Return
vs Sector (1yr)
-27.02%
vs ASX 200 (1yr)
-10.75%
$19.86 million
Market Cap
Share Issue
120.37 million
All Ords (%)
N/A
Short Sold
0%
Current Fundamentals
15 January
N/A
PE Ratio
EPS ($)
-
Earnings Yield
-
NTA ($)
-
0.00%
Dividend Yield
DPS ($)
-
Gross Div. Yield
-
Gross DPS ($)
-
Company Overview
Hexima Limited (HXL) is a biotechnology company actively engaged in the research and development of plant-derived defensin peptides for applications as human therapeutics. Its lead product candidate, HXP124 applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting a 132 patient Australian phase IIb clinical trial of HXP124 for onychomycosis.
Upcoming Calendar
Dividend History
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| No dividends paid in the last 5 years | ||||
See Upcoming Dividends for all ASX companies.
Announcements
| Date | Heading | Pages | File Size | Time |
|---|---|---|---|---|
Announcements provided by
Broker Consensus
The buy, hold and sell recommendations from Australian stockbroking firms are combined to form a "broker consensus". See the Consensus Data posts for more information.
HXL is not covered by a major broker,
or data from most recent compilation was omitted due
to not meeting QA guidelines.
Directors & Management
| Name | Title | Since | Bio |
|---|---|---|---|
| Mr Steven Michael Skala | Alternate Director | Mar 2020 |
|
| Mr Michael Douglas Aldridge | Chief Executive Officer, Managing Director | May 2019 |
|
| Professor Jonathan Paul West | Non-Executive Director, Non-Executive Chairman | Nov 2005 |
|
| Mr Scott Christian Robertson | Non-Executive Director | Nov 2018 |
|
| Professor Marilyn Ann Anderson | Chief Science Officer, Executive Director | Nov 2010 |
|
| Dr Nicole Louise van der Weerden | Chief Operating Officer, Executive Director | Dec 2014 |
|
| Mr Justin Zhen Nan Yap | Non-Executive Director | Jul 2018 |
|
| Marilyn A Anderson | Chief Science Officer | N/A | |
| Helen Molloy | Company Secretary, Finance Controller | N/A | |
| Robyn L Heath | Senior Vice President Product Development | N/A |
Director Transactions
HXL directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
There are no director transactions for code HXL in our database.
Shareholder Distribution
Shareholder Distribution data is unavailable.
Top 20 Shareholders
| Name | Shares | Capital |
|---|---|---|
| Dato Lim Sen Yap | 14,715,790 | 11.25% |
| Caroline House Superannuation Fund Pty Ltd (Caroline House S/F A/C) | 8,287,131 | 6.33% |
| Woobinda Nominees Pty Ltd (The Woobinda Family A/C) | 6,372,222 | 4.87% |
| Beta Gamma Pty Ltd (Walsh Street Super Fund A/C) | 5,736,586 | 4.38% |
| Gowing Bros Limited | 4,256,176 | 3.25% |
| Paul Orlin | 3,750,000 | 2.87% |
| Gowing Bros Ltd | 3,667,131 | 2.80% |
| HSBC Custody Nominees (Australia) Limited | 3,496,219 | 2.67% |
| Balmoral Financial Investments Pty Ltd | 3,051,090 | 2.33% |
| Adrienne Clarke | 3,028,938 | 2.31% |
| Hugh Morgan | 2,977,252 | 2.28% |
| Dalit Pty Ltd (Dalit Family A/C) | 2,500,000 | 1.91% |
| Dongrisha Pty Ltd (The Dongrisha Investment A/C) | 2,500,000 | 1.91% |
| Huysmans Pty Ltd (The Lama A/C) | 2,346,011 | 1.79% |
| Marilyn Anderson | 2,280,548 | 1.74% |
| Saxum Pty Ltd | 2,106,755 | 1.61% |
| Cranley Nominees Pty Ltd (Fitzroy Family A/C) | 2,007,674 | 1.53% |
| Pioneer Hi-Bred International Inc. | 2,000,000 | 1.53% |
| Andama Holdings Pty Ltd (J & M Barlow Pension A/C) | 1,851,057 | 1.41% |
| Mr Leon Francis Lachal & Mrs Susan Margaret Lachal (The Lachal Super Fund A/C) | 1,779,249 | 1.36% |
| All other shareholders | 39.87 % | |
The Top 20 Shareholders of HXL hold 60.13% of shares on issue.
HXL Share Price History
| Date | Close | Change | % Change | Open | High | Low | Volume | Turnover |
|---|---|---|---|---|---|---|---|---|
HXL Historical Data
Download up to 20 years of share price history.
| Year | Closing Price (30 June) | Last Trade |
|---|
Offical data as published by ASX. See more Data Downloads.
Company Details
Principal Activity: Research and development of plant-derived proteins and peptides for applications as human therapeutics.
Incorporated: --
Level 4, LIMS2, Plenty Rd
Melbourne VIC 3086
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.